Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2013

View Archived Issues

Combinatorial strategies to enhance antitumor efficacy of monoclonal antibodies

Functional polymorphism associated with a predisposition towards allergic asthma reported

Serum miRNAs as markers of early gastric cancer risk

Bayer begins new collaboration with Seattle Genetics

RegeneRx reports results from phase II RGN-137 trial in epidermolysis bullosa

Myriad Genetics to conduct BRCA testing for Tesaro's niraparib studies

Boston College patents new PDE11A inhibitors

CytRx reaches target enrollment in phase IIb aldoxorubicin trial

Discovery of ROR-gamma inverse agonists for the treatment of Th17-mediated autoimmune diseases

Prima BioMed to begin three phase II trials of CVac

Cytokinetics and Astellas form skeletal muscle activator collaboration

Nanobiotix to develop NBTX-IV together with the NCI

Preliminary results from phase II trial of DN24-02 in urothelial cancer

Mesoblast receives approval for trial of mesenchymal precursor cells

NICE recommends dapagliflozin in certain patients with type 2 diabetes

Zealand Pharma presents ZP-GA-1, a new glucagon analogue

Findings link FOXJ1 gene with Barrett's esophagus

Celgene presents new protein kinase inhibitors

Boehringer Ingelheim designs novel mGlu5 receptor modulators

Chiesi Farmaceutici divulges novel MAPK 14 inhibitors

QRxPharma provides update on MoxDuo NDA review

Verastem begins phase I trial of VS-4718 in advanced cancer

Phase I study of MORAb-066 commences

Vivus obtains European approval for avanafil

FDA grants fast track designation to Genervon's GM-604 in ALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...